Search

everythinglearnresearchcommunity

for

Search:↓

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.

The conversation discusses the use of vasodilators like Minoxidil, L-arginine, and Niacin for hair regrowth, with Minoxidil causing intolerable side effects for the original poster. It also highlights that certain medications, including Lisinopril, antidepressants, and statins, can cause hair loss.

The user claims to have successfully treated hair loss using natural supplements like collagen, L-lysine, zinc, B12, and bamboo shoot extract, without using the "Big 3" treatments (Minoxidil, finasteride, RU58841). The community is skeptical, demanding proof and emphasizing that the "Big 3" are proven effective, while natural remedies are often not.

Keratin fusion bonds are discussed as an alternative to clip-on hair patches for men with diffused thinning. The conversation explores different styling options for hair loss.

The conversation is about using topical valproic acid (VPA) for hair loss, focusing on its application method, usage frequency, and combination with other treatments like micro-needling. No specific experiences with VPA were shared.

Microneedling may enhance the effectiveness of liposomal minoxidil for hair loss. The user is also using tretinoin.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

The conversation is about a user obtaining a compounded treatment for hair loss, including 0.1% latanoprost, 0.2% melatonin, and 1% cetirizine. The user also uses 2.5 mg dutasteride, 5 mg minoxidil, and RU58841 daily, and is at Norwood 2.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

A user shared their positive experience with a hair transplant at Wimpole Clinic, performed by Dr. Malkani, and discussed using finasteride at a reduced dose due to side effects. They also mentioned avoiding minoxidil due to heart pain and taking supplements like biotin, marine collagen, viviscal, and krill oil.

A user is seeking suggestions for a custom hair lotion mix containing minoxidil, finasteride, caffeine, niacinamide, and biotin. Another user suggests adding tretinoin, topical valproate, and bimatoprost.

User discusses topical liposomal finasteride for hair loss, hoping to avoid breast growth side effect. Conversation includes using minoxidil, fluridil, and dermarolling, and mentions minimal systemic absorption of liposomal finasteride.

User shared progress pictures showing significant hair regrowth using a compounded solution of Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Latanoprost 0.005%. They reported no side effects and are satisfied with the results.

The user halted hair loss using 0.01% topical liposomal finasteride daily, with no side effects or regrowth, and recently added 5% minoxidil and low-level laser therapy. They recommend this conservative approach for those hesitant about finasteride.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

A new Latanoprost-based formula used by Hollywood celebrities to treat hair loss, with the formula containing minoxidil, tretinoin, melatonin, azelaic acid, zinc thymulin, vitamin B6, sandalore and methyl vanillate. It also mentions the potential of offering a combined sublingual minoxidil/oral dutasteride option in the future.

Bryan Johnson's new hair loss product, which includes peptides, is viewed skeptically by many, with concerns it may be a money grab rather than an effective treatment. Most users prefer proven treatments like finasteride and minoxidil, which are cheaper and have established results.

The user is considering using P5P to reduce high prolactin levels and is questioning if oral minoxidil could be contributing to the issue. They are also debating whether to switch from oral to topical minoxidil.

A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

The conversation is about difficulty finding a reputable source for Latanoprost or Bimatoprost in pure powder form or high concentrations for hair loss treatment, with only low concentration solutions being readily available.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

Exploring alternatives to Minoxidil for hair loss, such as Bimatoprost and Latanoprost, as well as potential treatments like Finasteride and RU58841.